Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 3, 2002, Pages 175-178

  Mamidi, Rao N V S ^a   Katneni, Kasiram ^a   Mullangi, Ramesh ^a   Ramanujam, Rajagopalan ^a  

^a DR REDDY S RESEARCH FOUNDATION   (India)

Author keywords

Bioavailability; PAT 5A; Pharmacokinetics; Rats

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PAT 5A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PYRIDINES; RATS; RATS, WISTAR; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036655732     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190454     Document Type: Article

References (14)

1. Leahy J.L., Bonner Weir S. and Weir G.C. (1992): β-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care, 15, 442-455.
2. Defronzo R.A., Bonadonna R.C. and Ferrannini E. (1992): Pathogenesis of NIDDM. A Balanced overview. Diabetes Care, 15, 318-368.
3. Olefsky J.M. and Nelan J. (1995): Insulin resistance and non-insulin dependent diabetes mellitus; cellular and molecular mechanisms. Am. J. Clin. Nutr., 61, 980S-986S.
4. Fujita T., Sugiyama Y., S., Sohda T., Kawamatsu Y., Iwatsuka H. and Suzuoki Z. (1983): Diabetes, 32, 804-810.
5. Momose Y., Meguro K., Ikeda H., Hatanaka C., Oi S and Sohda T. (1991): Chem. Pharm. Bull., 39, 1440-1445.
6. Hulin B., Clark D.A., Goldstein S.W., McDermott R.E., Dambek P.J., Kappeler W.H., Lamphere C.H., Lewis D.M. and Rizzi J.P. (1992): J. Med. Chem., 35, 1853-1864
7. Cantello B.C., Cawthorne M.A., Cottam G.P., Duff P.T., Haigh D., Hindley R.M., Lister C.A., Smith S.A. and Thurlby P.L. (1994): J. Med. Chem., 37, 3977-3985
8. Liver damage warnings for troglitazone. (1997) Scrip 2228:21.
9. NIH abandons Rezulin in diabetes trial. (1998) Scrip 2342:20.
10. Bhushan V., Lohray B.B., Sekhar Reddy A., Bheema Rao P., Chakrabarthi R. and Rajagopalan R. PCT-International Publication Number: WO 97/41120.
11. Lohray B.B., Vidya Bhushan., Sekhar Reddy A., Bheema Rao P., Jaipal Reddy N., Hari Kishore P., Haritha N., Reeba K.V., Chakrabarthi R., Rajagopalann R. and Kasiram K. (1999): Novel euglycemic and hypolipidemic agents; pyridyl and quinolinyl containing thiazolidinediones. J. Med. Chem., 42, 2569-2581.
12. Vikramadithyan R., Chakrabarthi R., Misra P., Premkumar M., Kumar S.K., Rao C.S., Ghosh A., Reddy K.N., Uma C and Rajagopalan R, (2000): Euglycemic and hypolipidemic activity of PAT-5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gama activity. Metabolism, 49, 1417-1423.
13. Mamidi N.V.S. Rao., Swaroop Kumar V.V.S., Kasiram K., Chaluvadi M. Rao., Shreeram S., Gangadhar S., Nataraj B., Hari Kishore P., Bhushan, V. and Subramaniam S. (2000): Validated HPLC method for determination of PAT-5A, an insulin-sensitizing agent in rat plasma. J. Pharm. Biomed. App., 22, 251-255.
14. Gibaldi M. and Perrier D. (1982): Pharmacokinetics, 2nd edn. New York: Marcel Dekker, pp. 409-417.